Trials & centers Ask your doctor
Pick a condition Recruiting trials A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer Phase 1 · Recruiting
City of Hope National Medical Center /ID# 281381, Duarte, California, United States City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914, Irvine, California, United States Sarah Cannon Research Institute at HealthONE /ID# 278785, Denver, Colorado, United States More sites A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) Phase 3 · Recruiting
MemorialCare Orange Coast Medical Center ( Site 0032), Fountain Valley, California, United States Orlando Health Cancer Institute ( Site 0018), Orlando, Florida, United States Lahey Clinic ( Site 0042), Burlington, Massachusetts, United States More sites Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Phase 3 · Recruiting
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States More sites A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine Phase 1 · Recruiting
Rush University Medical Center, Chicago, Illinois, United States University of Kansas Cancer Center, Fairway, Kansas, United States Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States More sites A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer Phase 2 · Recruiting
Site 0170-USA Mitchell Cancer Institute, Mobile, Alabama, United States Site 0143 - HonorHealth, Phoenix, Arizona, United States Site 0102 - University of Arizona Cancer Center, Tucson, Arizona, United States More sites Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors Phase 1 · Recruiting
City of Hope, Duarte, California, United States Stanford University, Palo Alto, California, United States University of California San Francisco, San Francisco, California, United States More sites CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2 · Recruiting
Northwestern University, Chicago, Illinois, United States A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors Phase 1 · Recruiting
University of Arkansas Medical School, Little Rock, Arkansas, United States University of California - Los Angeles, Los Angeles, California, United States UCSF, San Francisco, California, United States More sites ClinicalTrials.gov NCI-designated centers Comprehensive & clinical
California City of Hope Comprehensive Cancer Center
Duarte, California
Moores Comprehensive Cancer Center
La Jolla, California
Jonsson Comprehensive Cancer Center
Los Angeles, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
Chao Family Comprehensive Cancer Center
Orange, California
UC Davis Comprehensive Cancer Center
Sacramento, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Stanford Cancer Institute (SCI)
Stanford, California
Connecticut Yale Cancer Center
New Haven, Connecticut
Florida University of Florida Health Cancer Institute
Gainesville, Florida
Mayo Clinic Cancer Center
Jacksonville, Florida
Sylvester Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Georgia Winship Cancer Institute
Atlanta, Georgia
Kentucky Markey Cancer Center
Lexington, Kentucky
New Hampshire Dartmouth Cancer Center
Lebanon, New Hampshire
New York Montefiore Einstein Cancer Center
Bronx, New York
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Herbert Irving Comprehensive Cancer Center
New York, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Mount Sinai Tisch Cancer Center
New York, New York
Wilmot Cancer Institute
Rochester, New York
North Carolina UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Duke Cancer Institute
Durham, North Carolina
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina
Oklahoma Stephenson Cancer Center
Oklahoma City, Oklahoma
Oregon Knight Cancer Institute
Portland, Oregon
Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Texas Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas
Dan L Duncan Comprehensive Cancer Center
Houston, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Mays Cancer Center at UT Health San Antonio
San Antonio, Texas
Virginia University of Virginia Cancer Center
Charlottesville, Virginia
VCU Massey Comprehensive Cancer Center
Richmond, Virginia
NCI-Designated Cancer Centers, June 10, 2026
BeeWell does not give medical advice.